ISACA Updates CMMI Model with Three New Domains That Help Organizations Improve Quality and Performance
6.4.2023 14:00:00 EEST | Business Wire | Press release
In a tightening economic market, addressing enterprise performance can help organizations better weather challenges by reducing costs, creating efficiencies, and coming in on schedule while improving overall quality. ISACA’s Capability Maturity Model Integration, or CMMI, has been doing just that for enterprises for more than three decades, and is now out with a major model update with three new model domains—Data Management, People Management, and Virtual Work—that allow organizations even more flexibility to customize their CMMI adoption to their unique needs.
A mainstay in the performance improvement space for more than 30 years, CMMI practices have helped organizations worldwide elevate performance, improve quality, reduce inefficiencies, and better serve the needs of organizations and their customers. According to its most recent performance report, which tracks real results of companies that use CMMI, CMMI-appraised organizations achieved an 81.3% success rate for their targeted objectives, improved productivity by up to 77%, and improved product quality by up to 80%. In this latest version, CMMI’s maturity model concept has been streamlined to allow organizations greater flexibility when adopting CMMI.
Data Management
The CMMI Data Management domain and practices enable organizations to organize and use data within the bounds of business requirements. It also provides guidance on verifying data integrity to drive effective decision making and consistent communications to empower organizations to achieve performance goals.
People Management
The CMMI People Management domain and practices provide guidance to align an organization’s workforce to its business objectives, and it empowers individuals and workgroups for success.
Virtual Work
The CMMI Virtual Work domain and practices include identifying, assessing, and addressing virtual, remote, and hybrid work needs, constraints, and flexible solutions in a systematic and consistent manner.
These three new domains join five existing ones: Development, Services, Supplier Management, Security, and Safety.
“CMMI has a proven track record in addressing problems all across the organization, focusing on outcome-based performance for faster, cheaper and better results. This new model addresses and helps optimize key areas that are top of mind for many organizations right now around data quality and management as well as how they can ensure their people are performing at their full potential,” says Ron Lear, ISACA vice president, frameworks and models. “This just enhances what has already been the gold standard in providing a prioritized pathway to launch products, provide services, and manage suppliers to achieve goals with measurable outcomes, with added bonus of making everyone’s job easier along the way.”
To learn more, visit https://cmmiinstitute.com/products/cmmi/content-release. To view case studies from CMMI partner organizations such as Wipro, Avantare, and Whale Cloud, visit www.isaca.org/enterprise/cmmi-performance-solutions.
About ISACA
ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA is a global professional association and learning organization that leverages the expertise of its more than 170,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality. It has a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for underresourced and underrepresented populations.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005242/en/
Contact information
Bridget Drufke, bdrufke@isaca.org, +1.847.660.5554
Emily Ayala, communications@isaca.org, +1.847.385.7223
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
